布地奈德福莫特罗、孟鲁司特钠联合脱敏疗法治疗过敏性鼻炎哮喘综合征的效果
|
摘要
目的 :观察布地奈德福莫特罗、孟鲁司特钠联合脱敏疗法治疗过敏性鼻炎哮喘综合征(CARAS)的效果。方法 :选取2010年6月～2016年6月收治的80例CARAS者,随机分为对照组1、2、3和观察组。对照组1单独使用布地奈德福莫特罗,对照组2单独使用孟鲁司特钠,对照组3组联合使用布地奈德福莫特罗+孟鲁司特钠,观察组联合使用布地奈德福莫特罗+孟鲁司特钠+脱敏疗法。疗程3个月。治疗前后,检测患者CARAS临床症状评分、肺功能和血清免疫学IgE水平。结果 :治疗后,4组患者CARAS的鼻炎症状和哮喘症状评分均下降,且观察组下降程度更明显;所有患者肺功能改善,但4组间FEV1和PEFR比较没有统计学差异。所有患者血清IgE水平降低,观察组降低程度最大,对过敏反应的治疗效果更好。结论 :布地奈德福莫特罗、孟鲁司特钠联合脱敏疗法能够改善CARAS患者的主要临床症状、肺功能和过敏反应,治疗效果最好。
Objective To observe the effect of budesonide/formoterol, montelukast sodium combined with desensitization therapy in the treatment of allergic rhinitis asthma syndrome(CARAS). Methods 80 patients with CARAS treated for June, 2010 ～ June, 2016 were randomly divided into the control group 1, 2, 3 and the observation group. The cases in control group 1 were treated by budesonide/formoterol; the cases in control group 2 were treated by montelukast sodium; the cases in control 3 group were treated by budesonide/formoterol combined with montelukast sodium; the cases in observation group were treated by with budesonide/formoterol and montelukast sodium combined with desensitization therapy. The course of treatment is 3 months. Before and after treatment, the CARAS clinical symptom score, pulmonary function and serum immunological IgE level were detected. Results After treatment, four groups of patients with CARAS symptoms of rhinitis and asthma symptom scores decreased, and the observation group decreased more obviously. All patients' lung function were proved, but between the four groups FEV1 and PEFR have no statistical difference. The serum IgE levels were decreased in all patients, and the lowest in the observation group. Conclusion Budesonide/formoterol, montelukast sodium combined with desensitization therapy can improve the clinical symptoms, pulmonary function and allergic reactions in patients with CARAS and have the best treatment effect.
Objective To observe the effect of budesonide/formoterol, montelukast sodium combined with desensitization therapy in the treatment of allergic rhinitis asthma syndrome(CARAS). Methods 80 patients with CARAS treated for June, 2010 ～ June, 2016 were randomly divided into the control group 1, 2, 3 and the observation group. The cases in control group 1 were treated by budesonide/formoterol; the cases in control group 2 were treated by montelukast sodium; the cases in control 3 group were treated by budesonide/formoterol combined with montelukast sodium; the cases in observation group were treated by with budesonide/formoterol and montelukast sodium combined with desensitization therapy. The course of treatment is 3 months. Before and after treatment, the CARAS clinical symptom score, pulmonary function and serum immunological IgE level were detected. Results After treatment, four groups of patients with CARAS symptoms of rhinitis and asthma symptom scores decreased, and the observation group decreased more obviously. All patients' lung function were proved, but between the four groups FEV1 and PEFR have no statistical difference. The serum IgE levels were decreased in all patients, and the lowest in the observation group. Conclusion Budesonide/formoterol, montelukast sodium combined with desensitization therapy can improve the clinical symptoms, pulmonary function and allergic reactions in patients with CARAS and have the best treatment effect.
引文
[1]Bin X I, Dongqing X I, Jiang X, et al. Clinical Research on Psychosomatic Treatment of Combined Allergic Rhinitis and Asthma Syndrome[J].China Journal of Chinese Medicine, 2015(1):29-31.
[2]林士军,王桂杰,刘玉春.过敏性鼻炎哮喘综合征[J].临床肺科杂志, 2010, 15(11):1612-1614.
[3]陈俏容,刘国钧,刘胜华,等.不同途径吸入布地奈德气雾剂治疗儿童过敏性鼻炎哮喘综合征的临床效果对比[J].中国医药导报,2016, 13(3):110-113.
[4]魏晓红,程巍.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效分析[J].中国医药指南, 2015(6):2076-2077.
[5]张小朴,史锁芳.中医药治疗过敏性鼻炎-哮喘综合征研究概况[J].中国中医急症, 2015, 24(1):114-116.
[6]Zhang W, Zhang S, Sun L, et al. Lung Function Analysis of Epidemiological Survey of 184 Patients with Combined Allergic Rhinitis and Asthma Syndrome[J]. Journal of Guizhou Medical University, 2016,41(11):1340-1342.
[7]Smurthwaite L, Durham S R. Local IgE synthesis in allergic rhinitis and asthma[J]. Current Allergy and Asthma Reports, 2002, 2(3):231-238.
[8]王勇,应秀娟.小剂量糖皮质激素布地奈德吸入在支气管哮喘治疗中的应用[J].实用药物与临床, 2014, 17(2):199-202.
[9]陈挺剑.孟鲁司特钠联合布地奈德治疗支气管哮喘临床疗效观察[J].海峡药学, 2016, 28(10):141-143.
[10]陈菱菱,周美君,罗鸿波,等.布地奈德福莫特罗粉吸入剂联合尘螨变应原脱敏疗法治疗中重度支气管哮喘的临床研究[J].国际医药卫生导报, 2015, 21(1):52-55.
[11] Willson J, Bateman E D, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and longactingβ-agonists[J]. Appl Health Econ Health Policy, 2016, 12(1):447-59.
[12]李国胜,王海燕,杨红娟.孟鲁司特钠片的循证应用[J].山西医药杂志, 2016, 45(10):1174-1178.
[13]于超,王斌全.孟鲁司特联合布地奈德治疗过敏性鼻炎-哮喘综合征临床观察[J].中国现代药物应用, 2012, 06(11):84-86.
[14]巫翠华,宋冰,黄立霞,等.布地奈德/福莫特罗联合孟鲁司特钠治疗咳嗽变异型哮喘的疗效观察[J].国际呼吸杂志, 2011, 31(9):9-11.
[15]符徴.过敏性鼻炎的脱敏治疗[J].海南医学, 2011, 22(10):5-7.
[16]付书彩,游锦,刘丹.安脱达脱敏治疗过敏性鼻炎对鼻阻力、EOS及ECP的影响研究[J].中国现代医生, 2016, 54(30):13-15.
[2]林士军,王桂杰,刘玉春.过敏性鼻炎哮喘综合征[J].临床肺科杂志, 2010, 15(11):1612-1614.
[3]陈俏容,刘国钧,刘胜华,等.不同途径吸入布地奈德气雾剂治疗儿童过敏性鼻炎哮喘综合征的临床效果对比[J].中国医药导报,2016, 13(3):110-113.
[4]魏晓红,程巍.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效分析[J].中国医药指南, 2015(6):2076-2077.
[5]张小朴,史锁芳.中医药治疗过敏性鼻炎-哮喘综合征研究概况[J].中国中医急症, 2015, 24(1):114-116.
[6]Zhang W, Zhang S, Sun L, et al. Lung Function Analysis of Epidemiological Survey of 184 Patients with Combined Allergic Rhinitis and Asthma Syndrome[J]. Journal of Guizhou Medical University, 2016,41(11):1340-1342.
[7]Smurthwaite L, Durham S R. Local IgE synthesis in allergic rhinitis and asthma[J]. Current Allergy and Asthma Reports, 2002, 2(3):231-238.
[8]王勇,应秀娟.小剂量糖皮质激素布地奈德吸入在支气管哮喘治疗中的应用[J].实用药物与临床, 2014, 17(2):199-202.
[9]陈挺剑.孟鲁司特钠联合布地奈德治疗支气管哮喘临床疗效观察[J].海峡药学, 2016, 28(10):141-143.
[10]陈菱菱,周美君,罗鸿波,等.布地奈德福莫特罗粉吸入剂联合尘螨变应原脱敏疗法治疗中重度支气管哮喘的临床研究[J].国际医药卫生导报, 2015, 21(1):52-55.
[11] Willson J, Bateman E D, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and longactingβ-agonists[J]. Appl Health Econ Health Policy, 2016, 12(1):447-59.
[12]李国胜,王海燕,杨红娟.孟鲁司特钠片的循证应用[J].山西医药杂志, 2016, 45(10):1174-1178.
[13]于超,王斌全.孟鲁司特联合布地奈德治疗过敏性鼻炎-哮喘综合征临床观察[J].中国现代药物应用, 2012, 06(11):84-86.
[14]巫翠华,宋冰,黄立霞,等.布地奈德/福莫特罗联合孟鲁司特钠治疗咳嗽变异型哮喘的疗效观察[J].国际呼吸杂志, 2011, 31(9):9-11.
[15]符徴.过敏性鼻炎的脱敏治疗[J].海南医学, 2011, 22(10):5-7.
[16]付书彩,游锦,刘丹.安脱达脱敏治疗过敏性鼻炎对鼻阻力、EOS及ECP的影响研究[J].中国现代医生, 2016, 54(30):13-15.